
BEATLAB is revolutionizing cardiovascular analysis with a cost-effective, precise, and accessible technology for the early detection of cardiovascular disease (CVD). With 18 million deaths annually from CVD globally and over 500 million people living with the condition, the need for early detection is critical, as 80% of cases are preventable. BEATLAB addresses the lack of readily available methods for early and precise CVD sign detection by combining standard sensors with AI and digital twin-modeling, offering a non-invasive, cost-effective, readily available, and high-precision solution.

BEATLAB is revolutionizing cardiovascular analysis with a cost-effective, precise, and accessible technology for the early detection of cardiovascular disease (CVD). With 18 million deaths annually from CVD globally and over 500 million people living with the condition, the need for early detection is critical, as 80% of cases are preventable. BEATLAB addresses the lack of readily available methods for early and precise CVD sign detection by combining standard sensors with AI and digital twin-modeling, offering a non-invasive, cost-effective, readily available, and high-precision solution.
What they do: Develop BEATLAB, a non‑invasive AI + digital‑twin technology for early detection and localization of cardiovascular disease using standard sensors (PPG, sphygmomanometer).
Founded / HQ: Founded 2021, Gothenburg, Sweden.
Team size: Approximately 3 employees.
Recent funding: Grant funding announced Nov 1, 2023 (lead: Vinnova).
Early detection and precise localization of cardiovascular disease using non‑invasive diagnostics.
2021
Healthtech / Medtech
Grant announced Nov 1, 2023.
Grant entry associated with Oct 1, 2023.
Pre‑seed round listed with lead investor Chalmers Ventures AB.
“Vinnova and Chalmers Ventures AB have participated in funding events for the company.”